Alth ough endoscop ic sinus surgery is a well-document ed pro cedure fo r the treatm ent of chro nic sinusitis in children and adults, no study has been conducted to specifically investigat e its applicat ion in a ge riatric populat ion. We undertook to fill this void by analyzing the reco rds of 1,112 patients who had undergone endosco pic sinus surgery fo r chronic sinusitis in our department between April 1988 and Mar ch 1998. We catego rized these patient s by age. There were 171 patients (15.4%) in the geriatric group (age: '265yr), 837 patients (75.3%) in the adult group (age: 17 to 64), and 104 patients (9.4%) in the pediatric group (age :~1 6 yr). Wef ound that the geriatric gro up expe rience d a disproporti onately larger share of ope rative complications, but most of them were min or. Outcomes were similar in all three gro ups. We conclude that endosco p ic sinus surgery is a safe and effec tive treatm ent fo r older patients with chroni c sinusitis.
Introduction
As the size of the geriatric popul ation has grown in developed countries, 1 the illne sse s of older peopl e have becom e a more imp ortant part of medicine .' Sinu sitis has been ranked as the sixth most common chronic disease in the geriatric population.' One reason for the high incidence might be that mucu s production is decr eased in older people. ' The most common clin ical manifestations of chronic sinu sitis in older per sons are nasal stuffiness, postnasal drip , cough, imp aired olfactory functi on , sore throat , and fever of unkn own ori gin .' Chronic sinusitis can also cause hallucin ations, cognitive imp airment, and del irium. Adequ ate antibiotic ther apy with other auxiliary treatment is the first step in the management of geri atric sinusitis.' If the patient fails to respond to medi cal management, surgical treatm ent might be indicated. ' Since the late 1970s , functional endo scopic sinus surgery (FESS ) has become a common procedure for treating chronic sinusitis in adults.' More recently, it has been used to treat chronic sinusitis in ped iatric patients with promi sing result s."? Because there might be differences between ordinary FESS performed in adults and children, Poole coined the term pediatric endoscop ic sinus surgery (PESS) to differentiate the latter from the former.'?
To our knowledge, no study has thus far reported the experience of FESS performed on ger iatric patients. To fill this void, we analyzed the result s of what we call ge riatric endos cop ic sinu s surgery (GESS) at our institution and compared them with the results of ordinary FESS performed in adults and PESS performed in children.
M aterials and methods
In our dep artm ent , FESS has been used to treat chronic sinusitis with or with out polyps since 1988. FESS is indicate d when medi cal treatment has failed -failure bein g defined as an unsatisfactor y result after repe ated and appr opri ate antibiotic therapy and adequ ate auxili ary treatment. Repeated and appropriate antibiotic therapy mean s either continuous long-term antibiotic management or several inte rmittent co urse s of antibi otic s based on the result s of bacterial cultures . Depending on the clinical cour se and findin gs, auxiliary treatment can be added .Th is auxiliary treatment includes mucolytic agents, antihistamines, nasal steroids, and nasal douches. The indications for revision FESS are the same as those for primary surgeries-that is, another failure of medical management.
We includ ed in this study all patients who under went endoscopic sinus surgery for chronic sinusitis in our Pregnancy: Teratogenic Effects. Pregnancy Category C: Moxitloxacin wasnot teratogenic whenadmi nistered to pregnant rats duri ng organogenesis at oraldoses ashigh as500mglkg /day or 0.24limes themaximum recommended human dose based on systemic exposure (AUC), but decreased fetal body weights and slightly delayed fetal skeletal development (indicative of fetotoxicity) were observed. Intravenous administration of 20 mglkg /day(approximately equal to the maximum recommended human oral dose based uponsystemic exposure) to pregnant rabbits during organogenesis resultedin decreased fetal body weig htsanddel ayedfet al skeletal ossification. When rib andvertebral malformationswere combined, therewasanincreased fetal andlitter incidence of these effects.Signs of maternal toxicity in rabbits at this dose included mortality, abortions, mar ked reduction of foodconsumpt ion, decreased water intake, body weight lossand hypoacti vity. There wasno evidence of teratogenicity when pregnant Cynomolgus monkeys were given oral doses ashighas100 mglkg/day (2.5times themaximumrecommended human dose based upon systemic exposure) . An increased incidenceof smaller fetuses wasobserved at100mglkglday. lnanoral pre-and postnataldevel opment study conducted in rats,effectsobservedat500mglkglday included sli ghtincreases in duration ofpregnancy and prenatal loss, reduced pup birthwei ghtand decreased neonatal survival. Treatment-related maternal mortality occurredduring gesta-tionat500mglkg /day in thisstudy.
Sincetherearenoadequate orwell-controlled studies in pregna ntwomen, moxifloxacin shouldbeusedduringpregnancyonlyif thepotentialbenefit justifies the potential risk to thefetus. NursingMothers:Moxifloxacinisexcreted inthebreast milkofrats. Moxifloxacin mayalso beexcreted in human milk. Becauseof thepotential forseriousadverse reactions in infantsnurs ingfrommotherstaking moxifloxacin, adecision should bemade whether to discontinue nursingor to discontinuethe drug, taki nginto accou nt the importance of thedrugto the mother. Pediatric Use: Safety and effectiveness inpediatric patientsandadolescents less than18yearsofage have not been established. Moxifloxacin causes arthropathy in juvenile animals.(See WARNIN GS.) Geriatri c Use:In controlled multiple-dose clinical trials, 23% of patients recei ving moxifloxacin were greater than or equal to 65 years of age and 9% were greater than or equal to 75years of age . The clinical trialdata demonstrate that there is no difference in thesafety andefficacy of moxifloxacin in patients aged 65or older compared to younger adul ts.
ADVERSEREACTIONS
Cl inical eff icacy trials enrolled over4900moxifloxacin treated patients, of whom over4300 patients received the 400 mg dose. Mostadverse events reported in moxifloxacin trials weredescribed asmildto moderate in severity and required no treatment. Moxifloxacin wasdiscontinued dueto adverse reactionsthought to bedrug-related in 3.8% of patients. Adverse reactions, judgedby investigators to beat least possibly drug-rel ated, occurring in greater than or equal to 1% of moxifloxacin treatedpatients were: nausea (8%),diarrhea (6%), dizziness (3%), headache (2%), abdom inal pain (2%), vomiti ng (2%), taste perversion (1%), abnormal liver function test(1%), anddyspepsia(1%). Addi tional events, judged byinvestigators to beat least possibly drug-related, that occurred in greater than0.05% and lessthan 1% of moxifloxacin treated patients were:
BODY Additional adverseevents have been reported from worldwide post-market ing experience with moxifloxacin. A causal relationship to the use of moxifloxacin cannot bereadily determined duetothespontaneousnat ureof reporting of medical events,and thelackofcontrols.Theeventsinclude:anaphylactic reactionand anaphylactic shock.
LABORATORY CHANGES
Changes inlaboratoryparameters, without regardto drug relationship, whichare not listed above andwhich occurred in~2% of pat ients andat an incidence greater than incontrolsincl uded: increases inMCH, neutrophjs.wacs, PTratio, ionized calcium, chloride, al bumin,globulin, bilirubin; decreases in hemoglobin, RBCs, neutrophils, eoslmpms, basophils, PTratio, glucose, PO:?, bil irubin and amylase. It cannot bedetermined if anyof the above laboratory abnormal ities werecaused bythedrugortheunderlying conditionbei ngtreated.
DOSAGE ANOADMINISTRATION
The dose 01 AVELOX Tablets is one400mgtablet taken orally every 24 hours. The durationof therapy depends on thetypeof infection asdescribed below.
Infection·
Daily instructions should becommunicated to the pat ientwhen appropriate: Patients shou ld beadvised:
• thatrnoxitloxacln mayproduce changes in theelectrocardiogram (OTcinterval prolongation). • thatmoxifloxacinshould beavoided inpatientsreceiving Class IA(e.g. quinidine, procainamide) orClass III (e.g. amiodarone.sotalol) antiarrhythmic agents. • that moxifloxacin mayadd to the OTc prolongingeff ects ofother drugs such as cisaprlde, erythromycin, antipsychot ics,andtricyclic antidepressants. • to infor m theirphysician of anypersonal or family history of Olc prolongation or proar rhythmic conditions such asrecent hypokalemia, significant bradycardia, acutemyocardial ischem ia. • toinformtheirphysicia nofanyother medicationswhentakenconcurrentl y with moxif loxacin, including over-the-countermedications. • to contact their physician if they experience pal pi tationsor fai nting spells whi le taking moxif loxacin. • that moxifloxacin maybe taken with or withoutmea ls, and to drink fluids liberally.
• thatmoxi floxacin should betaken atleast 4 hours before or 8 hours after multivitam ins(containing ironor zinc), antacids(containing magnesium, calcium, or aluminum), sucraltaie. or Videx!> (didanosine)chewablelbuffered tablets or the pediatric powderlor oral solution. (See CLINICAL PHARMACOLOGY, Drug Inleraelions and PRECAUTIDNS, DrugInteraclions.) • that moxi floxacin maybe associatedwithhypersensi tivity reactions, including anaphylactic reactions, even following a single dose, andto discontinue the drugatthefirstsignofa skinrash or othe r signs of anallergic reaction. • to discontinuetreatment; rest and relrain'from exercise: andinform their physician if they experience pain, inflammation, or rupture ofa tendon. • that moxilloxacin may cause dizziness and lightheadedness: therefore.
patients should knowhowthey react to this drug beforethey operate an automobile or machinery or engage in activi ties requiring mental alertness or coordination. • that phototoxicity has been reportedin patie nts receivingcertain quinolones.
There was no photntoxlclty seen with moxifloxaci n at the recommended dose. In keepingwithgood medical practice, avoidexcessivesunlight or artificial ultraviolet light (e.g. tanning beds). 11 sunburn-like reaction or skin erupno ns occur , contact yourphysician. (See CLINICAL PHARMACOLO GY, Photosensitivity Potential.) • that convulsionshave been reported in patients recei ving quinolones, and they shouldnotify their physi cianbeforetakingthis drugif there is a history of this condition. Some reactions were accom panied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticar ia, and itching . Serious anaphylacticrea ctions require immediate emergency treatment withepinephrine. Moxifloxacin shou ld bediscontinued at the firstappearance of a skin rashor anyother sign ofhypersensitivity. Oxygen, intravenous steroids, andairwaymanagement, including intubation, maybeadministered asindicated. Severe andsometimes fatal events, some dueto hypersensi tivity, andsome of uncertain etiology, have been reported in patients receiving therapy with all antibiotics.Theseeventsmay besevereandgenerallyoccu r foll owing theaomlnistratlon of multiple doses. Clinical manifestations mayinclude oneor more of the following: rash, lever, eosinophilia , jaundice, andhepatic necrosis. Pseudomembranous colitis has been report ed with nearly all antibacterial agentsandmay rangein severityfrommild to life-threatening. Therefore, it is important to consider this diagnosis in pati ents who present with diarrhea subseque nt to the administration 01antibacterial agents. Treatment wi th antibacterialagents alters thenormal floraof thecolon andmay per mit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficife is one primary cause of "antibiotic-associ ated colitis."
After the diagnosis of pseudomembranous cons has been established. therapeutic measures should beinitiated. Mildcases of pseudomembranous coms usually respondtodrugdiscontinuation alone. Inmoderate tosevere cases,considerationshould begivento managementwithfluids andelectrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against C.difficife colitis. Al though not observed in moxifloxacin clinical trials, Achilles and other tendon ruptures thatrequiredsurgical repair or resulted in prolonged disability have beenreported withqunolones. Moxi floxacin should bediscontinued if thepatient experiences pain, inflammation. or rupture ofa tendon. Appropriate culture andsusceptibility testsshould be performed before treatment in orderto isolate andidentify organisms causing infectionandto determine thei r susceptibility to moxifloxacin. Therapy withAVELDXmaybeinitiated before results of these tests arekno wn; once results become available, appropriate therapy should becontinued.
PRECAUTIO NS

CONTRAINDICATIONS
Moxifloxacin is contraindicated in persons with a history of hypersensitivity to moxltloxacinor anymember of thequinolone class of antimicrobial agents. ing or afte r 29 GESS (15.2%), 87 FESS (9.5%), and 5 PESS (4.1%) procedures (table 2) . The difference in complica tion rates was statistically sig nifica nt between the GESS group and both the FESS (p = 0.02) and the PESS gro ups (p = 0.002).
WARNINGS
ENDOSCOPI C SINUS SURG ERY FOR THE TREATMENT O F C HRON IC SINUS ITIS IN G ERIATRIC PATIENTS
Table 1. Comparison of the characteristics of 191 geriatric endoscopic sinus surgeries (GESS) with those of 915 ordinary functional (FESS) and 121 pediatric (PESS) procedures
The 29 com plica tions in the GESS gro up occurred in 13 patient s with out polyps, 16 with nasal polyps, and 0 with antrochoa nal polyps. The co rresponding figures in the FESS gro up were 40, 44, and 3. In the PESS patients, these figures were 2, 2, and I.
Outcomes. Followup questionnaires yielded 547 usable responses . In the GESS group, 83 of 97 patients (85.6%) repo rted improvement , as did 300 of 400 FES S
Results
Patients. We identified 1,1 12patien ts who were eligi ble for analysis: 171 (15.4 %) in the GES S gro up, 837 (75.3%) in the FESS group, and 104 (9.4 %) in the PESS gro up.
The GES S group included 146 men and 25 wo men, aged 65 to 84 years (mea n: 70.3); 153 were between 65 and 74 years old, and 18 were 75 or older. The FESS group included 494 men and 343 wome n, age d 17 to 64 years (mea n age:37.9), while the PESS gro up was made up of 55 boys and 49 girls, age d 5 to 16 years (mean : 12.6).
Procedur es. The 1,112 patients underwe nt a total of 1,227 endoscopic sinus surge ries: 19 I GESS , 9 I5 FESS, and 12 I PESS. The indications for GESS were chronic sinusitis without polyps (n = 9 1 opera tions), with nasal polyps (n =97), and with antro- the FESS group were 474, 4 18, and 23, and in the PESS group they were 63, 47, and 11. The percentage of patient s with antrochoa nal polyps was significantly higher in the PESS grou p than in the FESS and GESS gro ups (p<O.O I) . Most procedu res were bilateral and primary, and except for the PESS gro up, most were performed with local anesthesia (table 1) .
Complications. Operative com plications occ urred dur-departm ent between April 1988 and March 1998. We categor ized these patien ts into three groups acco rding to their age at the time of surgery .The GESS gro up was made up of all patients 65 years or older. Patient s between 17 and 64 years of age were included in the ordinary FESS gro up, and patient s aged 16 years or younger were includ ed in the PESS group. A chart review was used to evaluate operative procedures and complicatio ns, and questi on nai res were mailed to all patients to assess the effec tive ness of their surgery and the incidence of postoperative symptoms. Patient s were give n a choice of indicating whether their symptoms had disappeared, were impro ved, were unchanged , or were worse. Patients were co nsidered to have improved if their sym ptoms had disappe ared or were alleviated to some degree.
Volume 80, Number 4 JIANG, HSU patien ts (75 .0%) and 42 of 50 (84.0 %) PES S pa tie nts.
T here was a sta tis tically sig nifica nt diffe re nce in improvem ent rates between the GESS and FES S gro ups (p = 0. 027 ), but not bet ween the GESS and PESS gro ups (p = 0.081 ) or the FE SS and PESS gro ups (p = 0.1 61 ).
A mo ng GESS pati en ts wi tho ut pol yp s, 7 repor ted no sy mptoms at all , 3 1 had improved, 6 we re unch anged, and 3 had worse ned. A mo ng the GES S pati en ts with nasal polyp s, the corresp on din g figures were 14, 29. 3. and 2. T he 2 GE SS pati ent s with antrochoanal pol yps who answered the survey both indicated that thei r sy mpto ms had imp ro ved. T his foll owup period ran ged from 7 months to 8 years and 4 mo nths (mea n: 3 yr, 6 mo).
A mo ng FESS pat ient s wi tho ut pol yp s. 18 had no sy mpto ms, 129 had improved, 50 we re unch anged, andl7 were worse . A mo ng those with nasal po lyps, the co rres po ndi ng figu res we re 16, 129, 25, and 7. A mong those with antroc hoa na l pol yp s who responded to the qu est ionn aire, 2 re ported no sy m pto ms at all , 6 had im pro ved , and I had worsened. Thi s fo llow up peri od ra nge d fro m 7 month s to 10 yea rs and 6 months (mea n: 3 yr, 9 mo).
Am on g PESS patients witho ut pol yp s, 4 had no sy mptom s, 13 had im proved, 3 were the sa me, and 2 had worsened. Th e co rres po nd ing figures fo r those with nasal pol yp s were 3, 16, 2, and 1. Among the 7 pat ient s with ant roch oanal pol yp s who answered, I rep ort ed no sy mptom s and 5 had imp ro ved . Th is followup per iod ranged from 7 month s to 9 ye ars and 2 month s (mea n: 3 yr, 7 mo).
Discussion
Altho ugh ch ro nic sinus itis is quite co m mo n in older people, the role of ag ing in the path oph ysiol ogy of ge riatric sinusitis is not clear. Decreased mu cu s produ cti on in the noses of older person s might be one res po nsible fac tor.' Furth ermore, it is not clear whe ther agi ng has any un iqu e effec t on the man agem ent of chro nic si nusi tis in the ge riatr ic popul ati on . Th er efore , geriatric sinus itis is usu all y incl ude d wi th adult sinusit is, and the prin ciples of man agem ent are essentially the sarne .v-"
FESS was introduced to treat chro nic sinusi tis in adults in the late 1970 s/ and it has been effective .'! Altho ug h pediatric sinusi tis ha s been co nsi de red to be a differen t disease entity fro m adult sinus itis, endoscopic sinus surgery is ju st as successful in children.v'P" However, it has not ye t been cl earl y dem on strated that endoscopic sinus surgery ca n be effec tive ly appl ied in the ge riatric age gro up. Moreover , altho ugh geriatric sinus itis is present in 17% of older per son s.' the frequ en cy of GESS has not been ment ion ed in the literature.>?
In our study , GESS accounted fo r 15.6% of all endosco pic sinus surgeries for chro nic sinus itis. Becau se GES S was per form ed more ofte n than PESS (9.9 %) in our dep artm ent , it see ms that ge riatric sinus itis is qu ite com -232 mon-or at least that it requi res surgic al treatment more ofte n than does pedi atri c sinusitis. Th erefore, we beli eve that geriatric sinus itis deser ves mo re att ent ion tha n it is curre ntly give n in the literatu re.
In our study . the techniques for G ESS were similar to those for FE SS. The fact that unil ater al surgery was more com mo n in GES S operatio ns (30 .4%) than in FE SS (2 1. 1%) imp lies that ge riat ric sinusi tis mi ght be so mewha t different from adult sinusi tis.
Altho ugh the ope rative techn iqu es we re similar, co mpli cati on s occ urred more often in the G ESS gro up ( 15.2%) tha n in the FESS (9 .5%) and PES S (4 . 1% ) gro ups.
Despit e its high er co mplica tio n rate, the GE SS gro up had a better improve me nt rate: 85.6% after a mean follow up o f 3 ye ars and6 month s. Th erefore, we co ncl ude that it is an effec tive treatm ent fo r chro nic sinusi tis in geriatric patie nts who fai l to resp on d to medi cal treatment.
